Selective estrogen receptor modulators (SERM) for the brain:: Recent advances and remaining challenges for developing a NeuroSERM™

被引:11
作者
Brinton, RD
机构
[1] Univ So Calif, Pharmaceut Sci Ctr, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA
[2] Univ So Calif, Pharmaceut Sci Ctr, Program Neurosci, Los Angeles, CA 90089 USA
关键词
estrogen; SERM; nafoxidene; tamoxifen; phytoestrogen; neurodegeneration; Alzheimer's disease;
D O I
10.1002/ddr.10090
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Estrogen regulation of cognitive function and prevention of neurodegenerative disease has come to be of major scientific and clinical importance. While these functions rank paramount among concerns of women during menopause, the neoplastic risks associated with estrogen and hormone replacement therapy lead most women to elect against hormone intervention during menopause or to seek alternative estrogens in an attempt to ameliorate menopause-associated deficits and disease risks. Development of an effective selective estrogen receptor modulator (SERM) for use as an alternative to hormone replacement therapy must address the issues of efficacy in and availability to the brain. A brief review of estrogen effects on cognition, neuroprotective capability, and disease prevention is provided followed by an analysis of current knowledge regarding SERM efficacy in brain. Lastly, the challenges that remain for developing an effective NeuroSERM(TM) are considered.
引用
收藏
页码:380 / 392
页数:13
相关论文
共 107 条
[31]  
Gerber B, 1999, Gynakol Geburtshilfliche Rundsch, V39, P136, DOI 10.1159/000022295
[32]   Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice [J].
Grandbois, M ;
Morissette, M ;
Callier, S ;
Di Paolo, T .
NEUROREPORT, 2000, 11 (02) :343-346
[33]   THE ANATOMY OF A MEMORY - CONVERGENCE OF RESULTS ACROSS A DIVERSITY OF TESTS [J].
GREENOUGH, WT ;
BAILEY, CH .
TRENDS IN NEUROSCIENCES, 1988, 11 (04) :142-147
[34]   Synthesis and pharmacology of conformationally restricted raloxifene analogues: Highly potent selective estrogen receptor modulators [J].
Grese, TA ;
Pennington, LD ;
Sluka, JP ;
Adrian, MD ;
Cole, HW ;
Fuson, TR ;
Magee, DE ;
Phillips, DL ;
Rowley, ER ;
Shetler, PK ;
Short, LL ;
Venugopalan, M ;
Yang, NN ;
Sato, M ;
Glasebrook, AL ;
Bryant, HU .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (08) :1272-1283
[35]  
GRILL HJ, 1991, AM J CLIN ONCOL-CANC, V14, pS21
[36]   Therapeutic potential of selective estrogen receptor modulators [J].
Gustafsson, JA .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1998, 2 (04) :508-511
[37]  
HAMMOND CB, 1994, FERTIL STERIL, V62, pS157
[38]  
HARPER MJK, 1967, J REPROD FERTIL, V13, P101
[39]   Estrogen for Alzheimer's disease in women - Randomized, double-blind, placebo-controlled trial [J].
Henderson, VW ;
Paganini-Hill, A ;
Miller, BL ;
Elble, RJ ;
Reyes, PF ;
Shoupe, D ;
McCleary, CA ;
Klein, RA ;
Hake, AM ;
Farlow, MR .
NEUROLOGY, 2000, 54 (02) :295-301
[40]  
HENDERSON VW, 2000, HORMONE THERAPY BRAI